Literature DB >> 8896492

The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women.

J J Carter1, L A Koutsky, G C Wipf, N D Christensen, S K Lee, J Kuypers, N Kiviat, D A Galloway.   

Abstract

To study the temporal relationship between serum antibody response and human papillomavirus type 16 (HPV-16) infection, a cohort of 325 university women were scheduled for examinations at 4-month intervals. At every examination, interviews were completed, cells were obtained for polymerase chain reaction-based testing and for Pap screening, and serum was obtained for testing with a HPV-16 capsid-capture ELISA. Seroreactivity was associated with detection of HPV-16 DNA and with increased numbers of sex partners. The median time to seroconversion was 8.3 months among women with incident HPV-16 infections. Within 16 months following HPV-16 DNA detection, 93.7% of women with prevalent and 67.1% of women with incident infections seroconverted. After seroconversion, antibody responses were maintained during follow-up among HPV-16 DNA-positive women. Women who seroconverted were 5.7 times (95% confidence interval = 2.4-13.4) more likely to have squamous intraepithelial lesions associated with the detection of HPV-16 DNA than were women who did not seroconvert.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8896492     DOI: 10.1093/infdis/174.5.927

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  86 in total

1.  Lower Genital Tract Infections and HIV in Women.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-12       Impact factor: 3.725

2.  Excellence in sexually transmitted infection (STI) diagnostics: recognition of past successes and strategies for the future.

Authors:  A Ronald; J Kuypers; S A Lukehart; R W Peeling; V Pope
Journal:  Sex Transm Infect       Date:  2006-11-29       Impact factor: 3.519

Review 3.  Should female sex workers be offered HPV vaccination?

Authors:  Maarten F Schim van der Loeff; Alex Vorsters; Elske Marra; Pierre Van Damme; Arjan Hogewoning
Journal:  Hum Vaccin Immunother       Date:  2019-05-07       Impact factor: 3.452

4.  Genital human papillomavirus (HPV) concordance in heterosexual couples.

Authors:  Alan G Nyitray; Lynette Menezes; Beibei Lu; Hui-Yi Lin; Dan'elle Smith; Martha Abrahamsen; Mary Papenfuss; Christine Gage; Anna R Giuliano
Journal:  J Infect Dis       Date:  2012-04-26       Impact factor: 5.226

Review 5.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

6.  Role of human papillomavirus in the pathogenesis of oral squamous cell carcinoma.

Authors:  Anastasios K Markopoulos
Journal:  World J Exp Med       Date:  2012-08-20

7.  Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions.

Authors:  Maxime J J Fleury; Antoine Touzé; Silvia de Sanjosé; F Xavier Bosch; Joellen Klaustermeiyer; Pierre Coursaget
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

8.  Detection and quantitation of human papillomavirus by using the fluorescent 5' exonuclease assay.

Authors:  A Josefsson; K Livak; U Gyllensten
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

9.  Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals.

Authors:  Jennifer E Cameron; Isaac V Snowhite; Anil K Chaturvedi; Michael E Hagensee
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

10.  Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses.

Authors:  Yevgeniy Y Studentsov; Gloria Y F Ho; Morgan A Marks; Robert Bierman; Robert D Burk
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.